SITC Advances in Cancer Immunotherapy™ Online Courses

Published: On Date

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description and Target Audience
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, advanced practitioners, emergency physicians and all members of the cancer team, the ACI program focuses on how to educate your patients about receiving inpatient/outpatient cellular therapies; including examples of practical implementation provided

Estimated time to complete activity: 25 Minutes

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Understand the patient journey and how to prepare a patient for these steps.

• To be informed of the many time points that require patient education and reinforcement.

• Develop an understanding about the varying pieces of education necessary for patient success.

• How to properly prepare patients and their caregivers for outpatient CAR-T cell therapy.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty and Disclosure of Conflicts of Interest

No relevant financial conflicts.

Faculty
Meaghan Ekstrom, BA, BSN, MSN, FNP-BC
Massachusetts General Hospital
Boston, MA

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Published Date: 12/01/2023

Expiration Date: 12/01/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. In the course Difficult-to-treat Cases, Subject Matter Expert- David A. Braun, MD, PhD of Yale School of Medicine has endorsed the effectiveness of Immunotherapy in treating patients with Renal Cell Carcinoma. There are 3 real life difficult to treat case scenarios that elaborate tests, treatment plans, and the outcomes. The Subject Matter Expert reinforced his treatment plans while sharing the risk factors involved using the results of various clinical trials.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Identify the benefits and risks of adjuvant immune checkpoint inhibitor (ICI) therapy with help of case studies.
• Recognize the differences between front-line ICI-based therapies for metastatic disease.
• Explain the treatment options for “PD-1—refractory” disease.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

David A. Braun, MD, PhD       

Assistant Professor, Goodman and Gilman Yale Scholar- Yale Cancer Center, Yale School of Medicine

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
Consultant/Advisor/Speaker: Exelixis, AVEO, Charles River Associates, Schlesinger Associates, Imprint Science, Insight Strategy, Trinity Group, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-305-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 12/01/2023 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published: On 10/05/2023

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

The course irAES associated with Cellular Therapies and T-cell Engagers starts with an overview of cellular therapies and bisepcific antibodies. Dr. Loretta Nastoupil of UT MD Anderson Cancer Center has described the immune related acute and late adverse events associated with CAR T-cell therapies and potential approches to management of toxicities. The case studies presented by Dr. Nastoupil help decide the best possible action plan for managing toxicities associated with CAR T-cell therapies in patients.

Estimated time to complete activity:  40 Minutes

Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Give a brief overview of the mechanism of action and common toxicities associated with cellular therapies and T cell engagers.

• List the multiple approaches that should be followed post treatment.

• Describe the immune related acute and late adverse events (toxicities) associated with CAR-T cell therapies.

• Describe similar acute toxicities associated with T-cell engagers and potential different approaches to management.

• Explain the action plan for the management of toxicities associated with CAR-T cell therapies.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty and Disclosure of Conflicts of Interest

Faculty
Loretta Nastoupil, MD
Associate Professor
UT MD Anderson Cancer Center
Texas, USA

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest
Researcher: BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
Consultant/ Advisor/ Speaker: Abbvie, Atara, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, Janssen, Merck, Novartis, Takeda

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Published: On 08/11/2023

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer. 

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete activity:  1 hour

Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Describe key immunotherapy targets that are useful for combination approaches.
• Describe immunotherapy-based combination treatment regimens currently under investigation.
• Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty
Gregory B. Lesinski, PhD, MPH
Co-Director, Translational GI Malignancy Program
Winship Cancer Institute of Emory University,
Atlanta, Georgia, USA

Disclosure of Conflicts of Interest
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 

Published Date: 06/30/2023

Expiration Date: 06/30/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Define the term biomarker.
• Explain the functions of biomarkers.
• Differentiate the biomarkers based on their types.
• Describe the use of biomarkers in various cancer treatments.
• Summarize the challenges of using biomarkers in the treatment of cancer.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

Dr. Paolo A. Ascierto, MD
Director of Department of Melanoma
UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
Istituto Nazionale Tumori – Fondazione “G. Pascale”
Napoli, Italy

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-162-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published Date: 06/01/2023

Expiration Date: 06/01/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Explain the Mechanisms of immune related Adverse Events in brief.
• Describe the other host factors that affect the risk of immune related Adverse Events.
• Summarize the differences in PD-L1 and CTLA-4 toxicities.
• Explain the response assessment process in a patient for the immunotherapy treatment.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

Pradnya Patil, MD, FACP
Associate Staff Oncologist
Taussig Cancer Center, Cleveland Clinic
Cleveland, OH

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-151-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published Date: 05/05/2023

Expiration Date: 05/05/2024

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete the activity: 1 hour

For additional information about the accreditation of this activity, please visit https://partnersed.com

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

• Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
• Differentiate between the adaptive immune system and the innate immune system.
• Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty:

Chrystal M. Paulos, PhD
Director of Translational Research, Cutaneous Malignancies
Winship Cancer Institute at Emory University

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Conflicts of Interest:
IP Rights: Ares Immunotherapy
Consulting Fees: Ares Immunotherapy
Founder/Owner: Ares Immunotherapy
Other (subcontracts): Obsidian, Lycera, ThermaFisher

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. 

Pharmacy Continuing Education

PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-142-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Instructions for Credit

During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Published: On 04/28/2023

Please note, this activity does not offer continuing education credit.

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Additional support for this activity provided by:

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

View all available ACI online offerings at www.sitcancer.org/acionline.

Estimated time to complete activity:  1 hour

Target Audience
This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives
At the conclusion of this activity, the participant should be able to:

• Describe the concept of Immunotherapy.
• Identify the various types of cancer immunotherapy.
• Describe the rationale for common approaches to cancer immunotherapy.
• Explain the response assessment process in a patient for the immunotherapy treatment.

Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

Faculty
Christian M. Capitini, MD
Associate Professor
University of Wisconsin-Madison

Disclosure of Conflicts of Interest
The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute

The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


 

Published 12/21/2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This interactive course, Toxicity Management provides information on incidence, onset, severity, and grading of immune-related toxicities and irAEs with immune checkpoint inhibitors. Dr. Alexa Meara and Dr. Pankti Reid have also presented cases focussing irAEs, treatment plan, and management. 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: December 21, 2022 - December 21, 2023

Estimated time to complete activity: 90 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the end of this activity, the participant should be able to:

• Identify immune-related toxicities by grade, onset, and incidence.
• Identify immune-related adverse events resulting from immune checkpoint inhibitors.
• Describe the adverse events and management of cellular therapies.
• Describe the precautions needed when immunotherapy is provided to special patient populations.

Faculty

Alexa S. Meara, MD

Associate Professor

Division of Oncology

Division Rheumatology and Immunology

The Ohio State Wexner Medical Center, Ohio

Pankti Reid, MD, MPH

Assistant Professor

University of Chicago Medical Center, Illinois

Department of Medicine- Division of Rheumatology

Committee on Clinical Pharmacology and Pharmacogenomics

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
 

Alexa Meara, MD - Consultant/Advisor/Speaker:  Abbvie, GSK, Amgen, Sanofi, Aurinia

Pankti Reid, MD - Royalty and Patent Beneficiary: Patent pending for use of interleukin 6 axis inhibitor for viral infection associated pneumonitis  

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit

During the period 12/21/2022 through 12/21/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hour. Designated for 1 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (1.5 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-494-H01-P

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 5/20/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Immune Checkpoint Inhibitors. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: May 20, 2022 - May 20, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Marina Chiara Garassino, MD - The University of Chicago

Natalie Vokes, MD - The University of Texas MD Anderson Cancer Center

Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre, Dublin

Diane Tseng, MD, PhD - University of Washington School of Medicine, Fred Hutchinson Cancer Research Center

Bonnie Bermas, MD - UT Southwestern Medical Center

Vickie Shannon, MD - The University of Texas MD Anderson Cancer Center

Sadia Ali, MD - UT Southwestern Medical Center

Nikhil I. Khushalani, MD - Moffitt Cancer Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the mechanisms of immune checkpoint inhibitors.
• Summarize recent updates in the use of immune checkpoint inhibitors clinically.
• Outline common toxicities with immune checkpoint inhibitors and their management.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-240-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This course is no longer available for credit.

Published May 23, 2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This interactive course provides an overview of the mechanisms of immune-related adverse events (irAEs) that may be caused by implementing cancer immunotherapy.  This module walks the learner through the various mechanisms of irAEs, as well as differentiating early and late irAEs which may be distinguished by distinct mechanisms.  Learners will also have the opportunity to apply the knowledge gained in this module through two case studies.  

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: May 23, 2022 - May 23, 2023

Estimated time to complete activity: 15 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the various mechanisms of irAEs as well as the types of irAEs that may result.
• Describe various irAEs as well as treatment for severe irAEs.
• Differentiate central vs. peripheral tolerance of irAEs.

Faculty
Pradnya Patil, MD, FACP

Associate Staff / Department of Hematology-Oncology

Cleveland Clinic, Cleveland

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Pradnya Patil, MD, FACP - Nothing to disclose.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period May 23, 2022 through May 23, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-279-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 3/24/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Skin Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: March 24, 2022 - March 24, 2023

Estimated time to complete activity: 3.75 hours

Faculty:

Allison Betof Warner, MD, PhD - Memoral Sloan Kettering Cancer Center

Isabella C. Glitza, MD, PhD - The University of Texas MD Anderson Cancer Center

Janice Mehnert, MD - NYU Langone Health

Michael K. Wong - MD, PhD - The University of Texas MD Anderson Cancer Center

Ryan J. Sullivan, MD - Harvard Medical School, Massachusetts General Hospital

Omid Hamid, MD - The Angeles Clinic and Research Institute

Jarushka Naidoo, MBBCH, MHS - Beaumont RCSI Cancer Centre Dublin

Kathy Madden, NP, RN, MSN, FNP-BC, AOCNP, APHN - NYU Langone Perlmutter Cancer Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of skin cancers.
• Summarize recent updates in cancer immunotherapy for skin cancers, including emerging toxicities and managment.
• Implement cancer immunotherapy for skin cancer into clinical pratice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number  - JA4008162-9999-22-130-H01-P

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/24/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Intratumoral Therapies, Vaccines, and Cytokines. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 24, 2022 - February 24, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Diwakar Davar, MMBBS, MSc - UPMC Hillman Cancer Center

Patrick Ott, MD, PhD - Dana Farber Cancer Institute

Adi Diab, MD - The University of Texas MD Anderson Cancer Center

Harriet Kluger, MD - Yale School of Medicine

Matthew J. Frigault, MD, MSc - Massachusetts General Hospital

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the mechanisms of intratumoral therapies, vaccines, and cytokines.
• Summarize recent updates in the use of intratumoral therapies, vaccines, and cytokines clinically.
• Outline common toxicities with intratumoral therapies, vaccines, and cytokines, and their management.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-073-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Head and Neck Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Jessica R. Bauman, MD - Fox Chase Cancer Center

Jessica L. Geiger, MD - Cleveland Clinic Cancer Center

Dan P. Zandberg, MD - UPMC Hillman Cancer Center

Tanguy Seiwert, MD - Johns Hopkins Medicine

Trisha Wise-Draper, MD, PhD - University of Cincinnati Cancer Center

Ranee Mehra, MD - University of Maryland

Ravindra Uppaluri, MD, PhD - Dana Farber Cancer Institute and Brigham and Women's Hospital

Sana Karam, MD, PhD - University of Colorado

Aarti Bhatia, MD - Yale School of Medicine

Sid Sheth, MD - UNC School of Medicine

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in the use for the treatment of head and neck cancers.
• Summarize recent updates in cancer immunotherapy for head and neck cancers as well as toxicity management for key disease states.
• Implement cancer immunotherapy for head and neck cancers into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-052-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This course is no longer available for credit.

Published 3/15/2022

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: March 15, 2022 - March 15, 2023

Estimated time to complete activity: 30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for cancer.
• Identify the various types and appropriate use of cancer immunotherapy.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Christian Capitini, MD

Associate Professor of Pediatrics Hematology/Oncology

University of Wisconsin - Madison

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Christian Capitini, MD - Consulting Fees: Nektar Therapeutics; Novartis; Elephas Bio

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period 3/15/2022 through 03/15/2023 participants must read the learning objectives and faculty disclosures and study the educational activity.

Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.3 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5  contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-110-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Cell Therapies and T Cell Engagers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Loretta Nastoupil, MD - The University of Texas MD Anderson Cancer Center

Tycel J. Phillips, MD - University of Michigan Health

Krina K. Patel, MD, MSc - The University of Texas MD Anderson Cancer Center

Hans Lee, MD - The University of Texas MD Anderson Cancer Center

Joanna C. Yang, MD, MPH - Washington University

Chelsea C. Pinnix, MD, PhD - The University of Texas MD Anderson Cancer Center

Yi Lin, MD, PhD - Mayo Clinic

Tania Jain, MBBS - Johns Hopkins University

Zainab Shahid, MD, FACP - University of North Carolina at Chapel Hill

Surbhi Sidana, MD - Stanford University

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the mechanisms of cell therapies and T cell engagers.
• Summarize recent updates in the use of cell therapies and T cell engagers clinically.
• Outline common toxicities with cell therapies and T cell engagers and their management
• Identify unique institutional resources required for the appropriate use of cell therapies.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-045-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/22

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Gynecologic Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Amy Bregar, MD - Massachusetts General Hospital

Roisin O'Cearbhaill, MD - Memorial Sloan Ketting Cancer Center

Mary L. Disis, MD, FACP - Univerisity of Washington

Kerry Reynolds, MD - Massachusetts General Hospital

Shannon Westin, MD - MD Anderson Cancer Center

Emese Zsiros, MD, PhD - Rosewell Park Cancer Institute

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of gynecologic cancers.
• Summarize recent updates in cancer immunotherapy for gynecologic cancers including emerging toxicities and management.
• Implement cancer immunotherapy for gynecologic cancer into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of  3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-104-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 3/2/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Hematologic Malignancies. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: March 2, 2022 - March 2, 2023

Estimated time to complete activity: 3.75hours

Faculty: 

Nina Shah, MD - University of California San Francisco

Surbhi Sidana, MD - Stanford University

Aaron Logan, MD, PhD - University of California San Francisco

Naval Daver, MD - The University of Texas MD Anderson Cancer Center

Michael Spinner, MD - Stanford University

Charalambos (Babis) Andreadis, MD, MSCE - University of California San Francisco

Samantha Shenoy, NP - UCSF Medical Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of hematologic malignancies.
• Summarize recent updates in cancer immunotherapy for hematologic malignancies, including emerging toxicities and management
• Implement cancer immunotherapy for hematologic malignancies into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-078-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 5/3/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Lung Cancer. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: May 3, 2022 - May 3, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Anne Chiang, MD, PhD -- Yale School of Medicine

Marianne Davies, NP, DNP, MSN, BSN --Yale School of Nursing

Roy S. Herbst, MD, PhD -- Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital

Hossein Borghaei, DO, MS -- Fox Chase Cancer Center

Mark Awad, MD, PhD -- Dana-Farber Cancer Institute

Sarah Goldberg, MD, MPH -- Yale School of Medicine

Henry S. Park, MD, MPH -- Yale School of Medicine

Scott N. Gettinger, MD -- Yale School of Medicine

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify cancer immunotherapy approaches in use for the treatment of lung cancers.
• Summarize recent updates in cancer immunotherapy for lunch cancers including emerging toxicities and management.
• Implement cancer immunotherapy for lung cancer into clinical practice appropriately.
• Describe the use of biomarkers to select appropriate cancer immunotherapies for lung cancer patients.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-239-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 3/10/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Monoclonal Antibodies and Antibody-Drug Conjugates. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: March 10, 2022 - March 10, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Komal Jhaveri, MD, FACP - Memorial Sloan Kettering Cancer Center

Nina Shah, MD - University of California San Francisco

David Ilson, MD, PhD - Memorial Sloan Kettering Cancer Center

Daniel Petrylak, MD - Yale School of Medicine

Patrick Brown, MD - Johns Hopkins University

Aditya Bardia, MD, MPH - Massachusetts General Hospital

Christian M. Captini, MD - University of Wisconsin-Madison

Hope Rugo, MD - University of California San Francisco Comprehensive Care Center
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the mechanisms of monoclonal antibodies and antibody-drug conjugates.
• Summarize recent updates in the use of monoclonal antibodies and antibody-drug conjugates clinically.
• Outline common toxicities with monoclonal antibodies and antibody-drug conjugates and their management.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-079-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 4/6/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Breast Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: April 6, 2022 - April 6, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Leisha Emens, MD, PhD - University of Pittsburgh

Daniel Stover, MD - The Ohio State University

Ashley Cimino-Mathews, MD - Johns Hopkins University

Laura Kennedy, MD, PhD - Vanderbilt University

Sagar Sardesai, MBBS - The Ohio State University

Margaret Gatti-Mays, MD, MPH – Ohio State University Comprehensive Cancer Center

Melissa Wilson, PA-C, MPAS - University of Pittsburgh

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of breast cancers.
• Summarize recent updates in cancer immunotherapy for breast cancers including emerging toxicities and management.
• Implement cancer immunotherapy for breast cancer into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 2.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-184-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Gastrointestinal Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity: 3.25 hours

Faculty: 

Ghassan K. Abou-Alfa, MD, MBA - Memorial Sloan Kettering Cancer Center

Arndt Vogel, MD - Medizinische Hochschule, Hannover, Germany

James J. Harding, MD - Memorial Sloan Kettering Cancer Center

Stephen L. Chan, MBBS, FRCP -The Chinese University of Hong Kong

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of gastrointestinal cancers.
• Summarize recent updates in cancer immunotherapy for gastrointestinal cancers including emerging toxicities and management.
• Implement cancer immunotherapy for gastrointestinal cancer into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.25 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.25 contact hours (0.325 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-006-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on MSI-High and TMB-High Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity:  3.75 hours

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.
• Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers and toxicity management for key disease states.
• Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately.
• Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

Faculty

Young Kwang Chae, MD, MPH, MBA - Northwestern University

Daniel McGrail, PhD - The University of Texas MD Anderson Cancer Care Center

Zsofia Stadler, MD - Memorial Sloamn Kettering Cancer Center

John Strickler, MD - Duke University Medical Center

Nicholas DeVito, MD - Duke University Hospital

Funda Meric-Bernstam, MD - The University of Texas MD Anderson Cancer Care Center

Neil Segal, MD, PhD - Memorial Sloamn Kettering Cancer Center

Mohamed Salem, MD - Atrium Health

Theresa Brown, PharmD, BCOP - Duke University Hospital

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-008-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 5/26/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Toxicity Management. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available:  May 26, 2022 - May 26, 2023

Estimated time to complete activity: 4.0 hours

Faculty:

Noha Abdel-Wahab, MD, PhD - The University of Texas MD Anderson Cancer Center

Adi Diab, MD - The University of Texas MD Anderson Cancer Center

Van Anh Trinh, PharmD - The University of Texas MD Anderson Cancer Center

Sumit Subudhi, MD, PhD - The University of Texas MD Anderson Cancer Center

Mehmet Altan, MD - The University of Texas MD Anderson Cancer Center

Nicolas L. Palaskas, MD - The University of Texas MD Anderson Cancer Center

Yinghong Wang, MD, PhD, MSc - The University of Texas MD Anderson Cancer Center

Maen Abdelrahim, MD, PhD, PharmD - Houston Methodist

Jennifer A. Wargo, MD, MMSc - The University of Texas MD Anderson Cancer Center

Michelle Rohlfs, APRN, FNP-BC, AOCNP - The University of Texas MD Anderson Cancer Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.
• Outline the best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.
• Describe management approaches for difficult or refractory immune-related adverse events.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 4.0 contact hours. Designated for 2.25 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 4.0 contact hours (0.4 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-241-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 4/21/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Biomarkers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: April 21, 2022 - April 21, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Allen Gown, MD - University of British Columbia

Andrew Coveler, MD - University of Washington / Fred Hutchinson Cancer Research Center

Eric Konnick, MD, MS - University of Washington

Nora Disis, MD, FACP - University of Washington

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Discuss biomarkers in clinical use with approved cancer immunotherapies.
• Summarize recent updates in the use of biomarkers for cancer immunotherapies.
• Implement the use of biomarkers to select appropriate treatments for patients with cancer.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.6 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-236-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

This course is no longer available for credit.

Published 2/9/2022

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on Genitourinary Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

Credit Available: February 9, 2022 - February 9, 2023

Estimated time to complete activity: 3.75 hours

Faculty: 

Jessica Clement, MD - Hartford Healthcare

Alexandra Drakaki, MD, PhD - UCLA

David F. McDermott, MD - Beth israel Deconess Medical Center

Tanya B. Dorff, MD - City of Hope

Jeannie Hoffman-Censits, MD - Johns Hopkins

Lisa Holle, PharmD, BCOP, FHOPA, FISOPP - UConn School of Pharmacy

Lidia P. Lopez, AGPCNP-BC - UCLA

Thomas Powles, MBBS, MD MRCP - Queen Mary University of London

Tracy Rose, MD, MPH - University of North Carolina at Chapel Hill

Virginia Seery, MSN, RN, AMP-BC, AOCNP - Beth Israel Deconess Medical Center

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify the cancer immunotherapy approaches in use for the treatment of genitourinary cancers.
• Summarize recent updates in cancer immunotherapy for genitourinary cancers including emerging toxicities and management.
• Implement cancer immunotherapy for genitourinary cancer into clinical practice appropriately.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-102-H01-P)

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.